Correlation Between Arvinas and Adaptimmune Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Arvinas and Adaptimmune Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arvinas and Adaptimmune Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arvinas and Adaptimmune Therapeutics Plc, you can compare the effects of market volatilities on Arvinas and Adaptimmune Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arvinas with a short position of Adaptimmune Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arvinas and Adaptimmune Therapeutics.

Diversification Opportunities for Arvinas and Adaptimmune Therapeutics

-0.03
  Correlation Coefficient

Good diversification

The 3 months correlation between Arvinas and Adaptimmune is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Arvinas and Adaptimmune Therapeutics Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptimmune Therapeutics and Arvinas is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arvinas are associated (or correlated) with Adaptimmune Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptimmune Therapeutics has no effect on the direction of Arvinas i.e., Arvinas and Adaptimmune Therapeutics go up and down completely randomly.

Pair Corralation between Arvinas and Adaptimmune Therapeutics

Given the investment horizon of 90 days Arvinas is expected to under-perform the Adaptimmune Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Arvinas is 1.66 times less risky than Adaptimmune Therapeutics. The stock trades about -0.04 of its potential returns per unit of risk. The Adaptimmune Therapeutics Plc is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  94.00  in Adaptimmune Therapeutics Plc on September 3, 2024 and sell it today you would lose (22.00) from holding Adaptimmune Therapeutics Plc or give up 23.4% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Arvinas  vs.  Adaptimmune Therapeutics Plc

 Performance 
       Timeline  
Arvinas 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Arvinas are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, Arvinas may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Adaptimmune Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Arvinas and Adaptimmune Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Arvinas and Adaptimmune Therapeutics

The main advantage of trading using opposite Arvinas and Adaptimmune Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arvinas position performs unexpectedly, Adaptimmune Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will offset losses from the drop in Adaptimmune Therapeutics' long position.
The idea behind Arvinas and Adaptimmune Therapeutics Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data